Easing the Disease Burden of Patients With Atopic Dermatitis

To participate in this activity, please:

Atopic dermatitis (AD) is a skin condition with substantial direct and indirect effects on patients. Guidelines for the management of AD were published in 2014, and while many of the tenets of basic AD skin care are well established, patients with AD are still not achieving optimal disease control in real-world practice. In this activity, Dr. Jonathan Silverberg reviews the burden of AD and the unmet needs within AD management today. Components of basic skin care from the 2014 guidelines are reviewed, followed by the most recent data supporting approved therapies and newly emerging oral and topical JAK-STAT inhibitors.

This program is also available as a podcast.  You may download it here: https://anchor.fm/atopicdermatitis

Course Credit:

0.75 AMA PRA Category 1 CreditsTM

Dates:

Opens: 2021-10-29
Closes: 2022-10-29

Target Audience:

This activity was developed for a national audience of dermatologists, pediatric dermatologists, allergists, nurse practitioners, physician assistants, and other clinicians involved in the management of patients with atopic dermatitis.

This activity is supported by independent educational grants from AbbVie and Incyte.

Accreditation and Certification

The Annenberg Center for Health Sciences at Eisenhower is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The Annenberg Center for Health Sciences at Eisenhower designates this enduring activity for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Additional Content Planners

Jessica Martin, PhD (Medical Writer)
No significant relationships to disclose.

Annenberg Center for Health Sciences

Staff at the Annenberg Center for Health Sciences at Eisenhower have no relevant commercial relationships to disclose.

All of the financial relationships listed for these individuals have been mitigated.

    Presenting Faculty

  • Jonathan I. Silverberg, MD, PhD, MPH

    Associate Professor
    Director of Clinical Research
    Director of Patch Testing
    George Washington University School of Medicine and Health Sciences
    Washington, DC

Learning Objectives

  • Describe the burden of disease experienced by patients with atopic dermatitis
  • Develop and modify, as needed, evidence-based treatment plans that address both symptoms and concerns of patients with atopic dermatitis
  • Summarize the latest research developments in the pharmacologic treatment of atopic dermatitis

Faculty Disclosures

Jonathan I. Silverberg, MD, PhD, MPH

Advisory board: AbbVie, Afyx, AOBiome, Arena, Asana, BiomX, Bluefin, Bodewell, Boehringer-Ingelheim, Celgene, Dermavant, Dermira, Eli Lilly, Galderma, GlaxoSmithKline, Incyte, Kiniksa, Leo, Luna, Menlo, Novartis, Pfizer, RAPT, Regeneron, Sanofi-Genzyme

Consultant: AbbVie, Afyx, AOBiome, Arena, Asana, BiomX, Bluefin, Bodewell, Boehringer-Ingelheim, Celgene, Dermavant, Dermira, Eli Lilly, Galderma, GlaxoSmithKline, Incyte, Kiniksa, Leo, Luna, Menlo, Novartis, Pfizer, RAPT, Regeneron, Sanofi-Genzyme

Research support: Galderma, Pfizer

Speakers bureau: Eli Lilly, Leo, Pfizer, Regeneron, Sanofi-Genzyme

Stockholder: AbbVie, BioNTech, Eli Lilly, Johnson & Johnson, Moderna, Pfizer, Regeneron